10,567
Total Claims
$4.2M
Drug Cost
1,096
Beneficiaries
$3,820
Cost/Patient
Peer Comparison vs. 110,156 Internal Medicine providers
-95%
Opioid rate vs peers
0.1% vs 2.2% avg
+171%
Cost per patient vs peers
$3,820 vs $1,411 avg
+198%
Brand preference vs peers
31.7% vs 10.6% avg
Opioid Prescribing
0.1%
Opioid Rate
13
Opioid Claims
$244
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
68% generic
Brand: 3,186 claims · $4.0M
Generic: 6,877 claims · $155K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 367 | $508K |
| Dulaglutide | 231 | $451K |
| Semaglutide | 232 | $363K |
| Semaglutide | 152 | $252K |
| Tirzepatide | 168 | $252K |
| Insulin Lispro | 110 | $154K |
| Teriparatide | 17 | $145K |
| Insulin Aspart | 100 | $142K |
| Insulin Glargine,hum.Rec.Anlog | 161 | $141K |
| Dapagliflozin Propanediol | 139 | $141K |
| Empagliflozin/Metformin Hcl | 69 | $115K |
| Insulin Detemir | 111 | $113K |
| Insulin Lispro Protamin/Lispro | 31 | $82K |
| Insulin Regular, Human | 52 | $82K |
| Insulin Degludec | 79 | $82K |
Prescribing Profile
Patient Profile
75
Avg Age
53%
Female
1.28
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data